Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2015

View Archived Issues

Novel small-molecule inhibitors confirm the involvement of PADI4 in neutrophil trap formation

FRAXA grant to Neurotrope preclinical behavioral studies of bryostatin for fragile X syndrome

AGTC and 4DMT collaborate in AAV-gene therapies for ophthalmic diseases

Curadev partners with Roche on IDO-1 and TDO inhibitors

FDA grants priority review to Adcetris supplemental BLA

FDA assigns obinutuzumab orphan drug status for follicular lymphoma

U.S. orphan drug status conferred on triheptanoin for fatty acid oxidation disorders

Preclinical evaluation of the selective FGFR inhibitor INCB-054828

FP-208, an mTOR inhibitor, shows potential for cancer in preclinical studies

An orally available MKNK1 inhibitor from Bayer

TetraLogic and Merck & Co. to collaborate on phase I trial of birinapant and pembrolizumab

Novel zefrafish model for detecting apoptosis

Euroscreen starts phase II trials of ESN-364 in uterine fibroids and polycystic ovary syndrome

SHAL Technologies receives NCI grant to fund preclinical testing of SH-7139

Uric acid as a novel predictive biomarker in ankylosing spondylitis

Pain Therapeutics regains rights to Remoxy from Pfizer

Nimbus Discovery patents IRAK-4 inhibitors

Pfizer's crizotinib receives FDA breakthrough therapy designation for ROS1-positive NSCLC

Pharmakea discloses autotaxin inhibitors

Astex Therapeutics develops prodrugs of gemcitabine and cytarabine

Olatec Industries patents compound for pain and inflammation

Sanford-Burnham Medical Research Institute patent describes EBI2 modulators

Relmada initiates proof-of-concept study for oral buprenorphine

scPharmaceuticals initiates pivotal trial of furosemide solution for subcutaneous administration

Inovio initiates phase I trial of HBV DNA vaccine INO-1800

Teva makes play for Mylan as Perrigo rejects Mylan proposal

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...